Clinicians Research roundup

EASD 2026: 7 additional updates worth knowing

October 2, 2026 · By Joe Zucchi, PA-C, MPAS

Download PNG ↓Original LinkedIn post ↗

1122 × 1402 px · PDF includes the original image and a link to this page.

About this visual

Seven additional obesity medicine updates highlighted at EASD 2026: survodutide, olatorepatide, trevogrumab, orforglipron, ABBV-295, KAI-4729, and ecnoglutide.

Sources & further reading

Original LinkedIn post ↗

These updates come from different studies, populations, treatment durations, and phases of development. Results are not head-to-head comparisons.

Related visuals

EASD 2026: 7 additional updates worth knowing

Pinch to zoom on touch devices. Open full image ↗